Business
-
Chinese OINDP developer CF PharmTech announced that it has completed a $50 million Series F financing round approximately six months after completing a $90 million financing round. Investors participating in the latest financing include BioTrack Capital,… Read more . . .
-
Meissa Vaccines has provided updates on two intranasal live attenuated vaccines (LAVs) based on its “codon deoptimized RSV vaccine platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines.” The company said that… Read more . . .
-
Tiziana Life Sciences has announced a new agreement with STC Biologics for manufacturing of its TZLS-501 inhaled anti-IL-6 receptor monoclonal antibody. The company said that it is also working with Sciarra Laboratories to develop a… Read more . . .
-
VistaGen Therapeutics has announced that it signed a deal giving EverInsight Therapeutics development and commercialization rights to Vistagen’s PH94B aloradine nasal spray for anxiety disorders in China, South Korea, and a number of other Asian countries.… Read more . . .
-
North Carolina-based Renovion said that it has raised $8.1 million in a Series A financing round for development of its ARINA-1 nebulized glutathione/bicarbonate/ascorbic acid formulation for the treatment of chronic lung diseases. ARINA-1, which is… Read more . . .
-
Tonix Pharmaceuticals has announced that it will acquire assets from Trigemina, Inc that include intranasal oxytocin for the treatment of migraine headaches. Trigemina had licensed the nasal spray, now called TNX-1900, from Stanford University, and… Read more . . .
-
Inhalation CDMO Vectura and inhaled drug developer Aerami Therapeutics (formerly Dance Biopharm) have signed an agreement for development of inhaled imatinib for the treatment of pulmonary arterial hypertension (PAH), the companies said. Aerami will pay nothing… Read more . . .
-
United Therapeutics has filed a patent infringement suit against Liquidia Technologies in the US District Court for the District of Delaware alleging infringement of US patents 9,604,901 and 9,593,066, which protect Tyvaso treprostinil inhalation solution. Both patents… Read more . . .
-
UCB said that it is paying $125 million up front, plus up to $145 million in potential milestone payments, to acquire Engage Therapeutics. Engage has a single candidate, Staccato inhaled alprazolam, which is in Phase… Read more . . .
-
Marinomed Biotech has announced that Fidia Farmaceutici will begin marketing Marinomed’s Carragelose-based nasal sprays in Italy in Fall 2020, and Sanova Pharma has signed an agreement to launch the new Carravin nasal spray in Austria… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden